在轻度缺血性中风患者中,强化与中度的基于他类药物的治疗方法:一个前性的多中心队列研究
Hai-Mei Fan1,2, Yong-le Wang1, Kai-Li Zhang3
1Department of Neurology First Hospital of Shanxi Medical University Taiyuan China.
Journal of the American Heart Association
|July 9, 2024
概括
与中剂量治疗相比,对轻度缺血性中风的高剂量他类药物治疗没有减少复发. 然而,高剂量的他类药物在亚洲人群中增加了内出血的风险.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在缺血性中风后,他类药物对脑血管事件的二次预防至关重要.
- 对于亚洲人口中轻度缺血性中风患者来说,最佳的他类药物强度仍然不清楚.
- 这项研究调查了高剂量与中剂量他类药物的有效性和安全性.
研究的目的:
- 为了比较高剂量和中剂量他类药物治疗在预防中风复发方面的有效性.
- 评估安全性,特别是与不同强度的他类药物相关的内出血风险.
- 评估亚洲患者在轻度缺血性中风后的强化他类药物治疗的益处.
主要方法:
- 一项多中心前性研究,涉及在发病72小时内轻度缺血性中风的患者.
- 高强度和中等强度他类药物治疗组之间的结果比较.
- 倾向性得分匹配和多变量考克斯分析被用于控制混因子.
主要成果:
- 在3个月和12个月的高强度和中等强度他类药物组中,中风复发率相似 (调整后的HR约1.1).
- 高强度他类药物治疗与3个月和12个月内内出血风险显著增加有关 (调整后HRs约1.8).
- 倾向性得分匹配的分析证实了考克斯比例危险分析的发现.
结论:
- 与中剂量治疗相比,高剂量他类药物治疗似乎没有降低轻度,非心脏源性缺血性中风复发的风险.
- 强化他类药物治疗可能会增加轻度缺血性中风患者内出血的风险.
- 研究结果表明,需要仔细考虑亚洲人口中风后的他类药物强度.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
628
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
628
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177


